Liberty Defense Lands HEXWAVE™ Deal with Infectious Disease Lab

Event summary

  • Liberty Defense secured a contract to deploy its HEXWAVE™ walkthrough screening system at an infectious disease laboratory.
  • The system will screen employees and visitors, enhancing safety with AI-powered threat detection.
  • HEXWAVE™ combines active millimeter-wave imaging to detect metallic and non-metallic threats.
  • Liberty's amended 2025 Omnibus Incentive Plan received final approval from the TSX Venture Exchange.
  • The plan authorizes the grant of stock options and other equity awards, not to exceed 10% of outstanding shares.

The big picture

Liberty Defense's contract with an infectious disease laboratory underscores the growing demand for advanced security solutions in high-risk environments. The deal highlights the strategic importance of AI-powered threat detection in safeguarding critical research facilities. The approval of the 2025 Omnibus Incentive Plan further solidifies Liberty's governance framework, positioning the company for sustained growth in the security technology sector.

What we're watching

Market Expansion
Whether Liberty can replicate this success with other high-security facilities.
Technology Validation
How the on-site trial results influence future deployments.
Regulatory Compliance
The impact of the 2025 Omnibus Incentive Plan on shareholder value.